Merck's verubecestat reduces beta amyloid levels but fails to improve cognition, function

Data published in the New England Journal of Medicine from the discontinued Phase II/III EPOCH trial in 1,958 patients with mild to moderate Alzheimer's disease showed that verubecestat (MK-8931) from Merck & Co. Inc. (NYSE:MRK) reduced beta amyloid levels but failed to improve

Read the full 437 word article

User Sign In